Source comparison
CJC-1295 no DAC & Ipamorelin: Before and After Comparison
The following table compares expected outcomes across three common dosing protocols based on aggregated research data from peptide studies evaluating body composition changes over 12 weeks. Conservative (once daily, fasted AM) 100mcg each peptide (200mcg total
This comparison does not assign a generated winner or score.
- The following table compares expected outcomes across three common dosing protocols based on aggregated research data from peptide studies evaluating body composition changes over 12 weeks.
- Conservative (once daily, fasted AM)
- 100mcg each peptide (200mcg total)
- 2-4% body fat reduction
- 1-2kg lean mass gain
- Minimal; occasional mild flushing or injection site redness
- Ideal for first-time users or those over 50; preserves safety margin while producing measurable results
- Standard (twice daily, AM fasted + pre-bed)
- 200mcg each peptide (400mcg total)
- 4-7% body fat reduction
- 2-4kg lean mass gain
- Mild; transient water retention in 15-20% of users, resolves within 2-3 weeks
- Optimal risk-reward ratio for most users; captures both endogenous GH pulses for maximum efficacy
- Aggressive (twice daily, higher dose)
- 300mcg each peptide (600mcg total)
- 5-8% body fat reduction
- 3-5kg lean mass gain
- Moderate; increased risk of numbness/tingling (carpal tunnel symptoms from fluid retention), requires monitoring
- Reserved for advanced users with prior peptide experience; diminishing returns above 200mcg per dose in most individuals
- The Standard protocol (100mcg of each peptide dosed twice daily) represents the evidence-based sweet spot. It produces 70-80% of the maximal possible results with minimal side effect burden and significantly lower cost than the Aggressive protocol. Users should not progress to higher dosing unless the Standard protocol has been maintained consistently for 12+ weeks with suboptimal results, as most non-response cases trace to dosing inconsistency, storage errors, or inadequate training stimulus rather than insufficient peptide dose.